Compare TY & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TY | EYPT |
|---|---|---|
| Founded | 1929 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | N/A | 2005 |
| Metric | TY | EYPT |
|---|---|---|
| Price | $31.99 | $15.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $31.00 |
| AVG Volume (30 Days) | 36.9K | ★ 1.7M |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 4.78 | N/A |
| Revenue | N/A | ★ $7,539,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $965.51 |
| P/E Ratio | $6.79 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.54 | $3.91 |
| 52 Week High | $35.05 | $19.11 |
| Indicator | TY | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 33.00 | 48.23 |
| Support Level | $31.98 | $11.88 |
| Resistance Level | $33.58 | $18.99 |
| Average True Range (ATR) | 0.41 | 1.23 |
| MACD | -0.11 | -0.04 |
| Stochastic Oscillator | 27.94 | 33.88 |
Tri-Continental Corp is a United States-based closed-end management investment company. It invests to produce future growth of both capital and income while providing reasonable current income. The fund is divided into two equal segments namely, the equity segment uses quantitative models to select individual stocks whereas the Flexible capital income segment invests across a company's investable capital structure, including stocks, bonds, and convertible securities. The Fund invests in a range of sectors, which include consumer discretionary, consumer staples, energy, financials, healthcare, industrials, information technology, industrials, materials, real estate, telecommunication services, utilities, aerospace and defense, banking, chemicals, and others.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.